
BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
AfD faction in western Germany ousts councilman for firebrand speech - 2
Former hostage Eitan Mor on Hamas: ‘They will not give up until the last Israeli is gone' - 3
From candy cane fishing to ornament switcharoo, here are some of the best games you can play with your loved ones this holiday season - 4
Instructions to Explore the Therapy Choices for Cellular breakdown in the lungs - 5
The Best Computer games for Multiplayer Fun
Find the Excellence of Old style Expressive dance: Encountering the Effortlessness and Polish of Dance
Remote Headphones: Upgrade Your Sound Insight
Sydney Sweeney's American Eagle campaign and Kendrick Lamar's Super Bowl performance were among the 10 biggest pop-culture moments of 2025
Only 30% of young people in Israel optimistic about future, Aluma survey reveals
EU calls on Western Balkans to step up reforms for membership
From Dread to Certainty: Individual Accounts of Strengthening
Pick Your Top Method for starting the Morning
Several killed in Ukraine and Russia after cross-border attacks
Protester climbs on to balcony of Iranian embassy in London











